In these trials, passive administration of VRC01, a broadly neutralizing antibody against human immunodeficiency virus that targets the HIV CD4-binding site, had some anti-HIV effect in 24 persons with chronic HIV infection. Therapeutic administration of monoclonal antibodies has revolutionized treatment options in oncology, rheumatology, endocrinology, gastroenterology, neurology, and the field of infectious diseases. 1 , 2 The use of broadly neutralizing antibodies (bNAbs) against human immunodeficiency virus (HIV) is a potential approach to the prevention of HIV infection and its therapy and cure. 3 , 4 VRC01 is a bNAb that targets the CD4-binding site of the HIV envelope glycoprotein. VRC01 has been shown to neutralize approximately 90% of a broad panel of 190 group M HIV envelope pseudotyped viruses with a mean 50% inhibitory concentration (IC 50 ) of 0.33 μg per milliliter. 5 Passive administration . . .